特发性非肝硬化性门脉高压1例并文献复习

doi:10.3969/j.issn.1672-5069.2022.05.036

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (5): 750-752.doi: 10.3969/j.issn.1672-5069.2022.05.036

特发性非肝硬化性门脉高压1例并文献复习

杨静, 程艳丽

100016 北京市清华大学第一附属医院消化内科

收稿日期:2022-02-18 出版日期:2022-09-10 发布日期:2022-09-22
通讯作者: 程艳丽,E-mail:chengyanli001@126.com
作者简介:杨静,女,37岁,医学硕士,主治医师。主要从事肝病和胃肠道早癌诊治研究。E-mail: hongxiayj1984@sina.com

Idiopathic non-cirrhotic portal hypertension: one case report and literature review

Yang Jing, Cheng Yanli

Department of Gastroenterology, First Affiliated Hospital, Tsing Hua University, Beijing 100015, China

Received:2022-02-18 Online:2022-09-10 Published:2022-09-22

摘要/Abstract

关键词: 特发性非肝硬化性门脉高压, 病理组织学, 诊断, 文献复习

Key words: Idiopathic non-cirrhotic portal hypertension, Histopathology, Diagnosis, Literature review

杨静, 程艳丽. 特发性非肝硬化性门脉高压1例并文献复习[J]. 实用肝脏病杂志, 2022, 25(5): 750-752.

Yang Jing, Cheng Yanli. Idiopathic non-cirrhotic portal hypertension: one case report and literature review[J]. Journal of Practical Hepatology, 2022, 25(5): 750-752.

[1]De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019, 4(5):399-411.
[2]Lee H, Rehman AU, Fiel MI. Idiopathicnoncirrhotic portal hypertension: An appraisal. J Pathol Transl Med,2016,50(1):17-25.
[3]Guido M, Sarcognato S, Sacchi D. Pathology of idiopathic non-cirrhotic portal hypertension. Virchows Archiv,2018,473(1):23-31.
[4]Verhei J, Schouten JNL, Komuta M,et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology,2013,62(7):1083-1091.
[5]陈功海,王广川,张春清. 特发性非肝硬化门静脉高压症诊治进展. 中华消化病与影像杂志( 电子版),2021,11(3):132-138.
[6]Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int, 2018, 12 (Suppl 1):148-167.
[7]Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS,2009,23(12):1511-1518.
[8]Schouten JNL, García-Pagán JC, Valla DC, et al. Idiopathic noncirrhotic portal hypertension. Hepatology, 2011,54:1071-1081.
[9]Koot BGP, Alders M, Verheij J, et al. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension. J Hepatol, 2016,64(4):974-977.
[10] Eapen CE, Nightingale P, Hubscher SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated Gut diseases and prognostic factors. Dig Dis Sci,2011,56(1):227-235.
[11] Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS,2010,24(8):1171-1176.
[12] Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol,2011,54:455-461.
[13] Seinen ML,van Asseldonk DP,de Boer NK,et al. Nodular regenerative hyperplasia of the liver in patients with IBD treated with allopurinol-thiopurine combination therapy. Inflamm Bowel Dis,2017,23( 3): 448-452.
[14] Schouten JN,Verheij J, Seijo S. Idiopathic non-cirrhotic portal hypertension: a review. Orphanet J Rare Diss,2015,10: 67.
[15] Sarin SK,Kumar A. Noncirrhotic portal hypertension. Clin Liver Dis,2006,10(3): 627-651.
[16] Sato Y, Nakanuma Y. Role of endothelial-mesenchymal transition inidiopathic portal hypertension. Histol Histopathol,2013,28( 2):145-154.
[17] Khanna R,Sarin SK. Non-cirrhotic portal hypertension-diagnosis and management. J Hepatol,2014,60(2): 421-441.
[18] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol, 2016,64(1): 179-202.
[19] Guido M, Alves VAF, Balabaud C, et al. International Liver Pathology Study Group. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology,2019,74( 2): 219-226.
[20] 何福亮,马琳,李悦榕,等. 非肝硬化性门脉高压的临床诊断.实用肝脏病杂志, 2022,25(1):1-4.
[21] Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol, 2012, 56(Suppl. 1): S25-38.
[22] Elkrief L, Rautou PE. Idiopathic non-cirrhotic portal hypertension: the tip of the obliterative portal venopathies iceberg. Liver Int, 2016,36(3):325-327.

特发性非肝硬化性门脉高压1例并文献复习

Idiopathic non-cirrhotic portal hypertension: one case report and literature review

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗楠, 李荣宽. 肝硬化并发自发性细菌性腹膜炎诊治现状[J]. 实用肝脏病杂志, 2022, 25(5): 616-619.
[2]	米朦, 卢秉久, 王学良, 王晓彤, 郑佳连. 代谢相关性脂肪性肝病患者血脂分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 653-656.
[3]	骆苏彦, 李婷婷, 王亚奇, 齐林. 原发性胆汁性胆管炎患者外周血Treg/Th17细胞相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 673-676.
[4]	龚豪, 黄丽, 张庆红, 李涛, 史秀岩. 应用尿微量白蛋白、β2-微球蛋白和N-乙酰-β-D氨基葡萄糖苷酶评估失代偿期肝硬化患者肾损伤效能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 681-684.
[5]	黄娟, 张吉琛. MRI LAVA扫描技术评估布-加综合征患者侧支循环研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 689-692.
[6]	施莹, 柏根基, 孙阳. 多模态MRI对肝硬化增生性结节与小肝癌的鉴别诊断价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 722-725.
[7]	中国医药生物技术协会慢病管理分会. 肝硬化合并糖尿病患者血糖管理专家共识[J]. 实用肝脏病杂志, 2022, 25(5): 761-S1.
[8]	陈梦绮, 范建高. 美国非酒精性脂肪性肝病诊断与治疗临床实践指南简介^*[J]. 实用肝脏病杂志, 2022, 25(5): 762-S16.
[9]	莫金英, 余希, 余雪平, 吴丽华, 瞿志军. FibroTouch诊断乙型肝炎病毒携带者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 480-483.
[10]	罗真真, 田海英, 葛建华, 纪元. 慢性丙型肝炎患者血清N-寡糖和胆汁酸水平变化判断肝纤维化临床价值分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 504-507.
[11]	付丽红, 高月求, 王晓琳, 刘坤, 李曼, 黄凌鹰. 38例药物性肝损伤患者肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 512-516.
[12]	汤磊, 彭蕾, 叶珺, 张振华, 邹桂舟. 影响慢性乙型肝炎患者进展为肝硬化的多因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 538-541.
[13]	李芳, 王衍森, 翁璐昕. 高频超声肝实质纹理特征定量联合血清AFP-L3水平评估乙型肝炎肝硬化患者肝功能分级价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 542-545.
[14]	郑丽雅, 田澄, 李娜. 剪切波弹性成像技术联合多参数评估肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 546-549.
[15]	王宝锋, 马彦高, 李义, 曾宪强, 周进学. 增强MRI扫描在乙型肝炎肝硬化背景下对原发性肝癌的诊断价值分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 554-557.